Global Cervical Dysplasia Market Is Anticipated To Witness Growth Due To Growing Incidences Of Cervical Cancer And Rising Awareness Regarding Cancer Diagnosis

 

Cervical Dysplasia 

Overview:

Cervical Dysplasia is a condition where abnormal cells form on the cervix, which is the lower portion of the uterus. It occurs most often in women who are childbearing age and are infected with the human papillomavirus (HPV). Although cervical dysplasia is not cancer, it can develop into cervical cancer if it is not diagnosed and treated early. There are two types of cervical dysplasia. First is mild, which is characterized by a few abnormal cells. This type of dysplasia will clear up on its own. However, a mild form of dysplasia may require periodic Pap smears to check for changes. Another form of dysplasia is moderate, which is characterized by a larger number of abnormal cells. Treatment for moderate dysplasia involves cryotherapy, surgical removal, or ablation of the affected area. High-grade squamous intraepithelial lesion is a severe form of dysplasia. This is the most common type of cervical dysplasia.

Market Dynamics:

Growing product approvals is estimated to augment growth of the Global Cervical Dysplasia Market during the forecast period. For instance, HPV DNA Diagnostic Kit by SANSURE BIOTECH INC., was approved by the China National Medical Products Administration in January 2022. This kit has been developed with 13 types of high-risk genotypes and advanced magnetic beads technology, it is capable of screening cervical cancer. Moreover, increasing costs of devices is anticipated to restrain growth of the global cervical dysplasia market during the forecast period.

Impact of COVID-19:

The outbreak of COVID-19 was first witnessed in December 2019, in Wuhan. Later on, this disease spread to more than a 100 nations.  It was declared as a public health emergency by the World Health Organization in 2020.  This led to shutting down of many businesses and affected the economy of many nations. COVID-19 affected the healthcare sector in a severe manner, as the number of people suffering from the disease were increasing daily in all countries. Lockdowns were imposed to prevent the transmission of the virus. Hospitals were almost full and COVID-19 patients were prioritized for treatment. This hampered the growth of the Global Cervical Dysplasia Market, as these treatments were either delayed or postponed.

Key Takeaways:

The Global Cervical Dysplasia Market is estimated to witness robust growth, exhibiting CAGR of XX% during the forecast period, owing to increasing expansion by key players. For instance, Sierra Oncology and GlaxoSmithKline Plc., declared their strategic partnership in April 2022. Under this partnership, Sierra will be acquired by GSK for US$ 55 per share of common stock in cash.

North America is anticipated to witness significant growth in the global cervical dysplasia market over the forecast period, due to growing incidences of cervical cancer.

Key Players Active In The Global Cervical Dysplasia Market Are Abbott Laboratories, Becton, Dickinson, and Company, Asieris Pharmaceuticals, Bristol-Myers Squibb Company, ASKA Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, KinoPharma, Inc., Micromedic Technologies Ltd., CooperSurgical, Inc., Karl Kaps GmbH & Co. KG, BetterLife Pharma, Inc., Hologic, Inc., PDS Biotechnology Company, and Polaris Pharmaceuticals, Inc.

 

Comments

Popular posts from this blog

Forging has significant application in creation of various metal for wide range of applications

Ginseng Market Outlook, Analysis and forecast up to 2028

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19